2028, FDA Approval, Licensing and Pharmaceuticals

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

2028

FDA Approval

Licensing

Pharmaceuticals

Emergent BioSolutions Announces 2021 Financial Guidance, Provides Preliminary 2020 Results

The Pharma Data

JANUARY 9, 2021

This growth primarily reflects increased sales of contract development and manufacturing (CDMO) services to pharmaceutical and biotechnology innovators and government/non-government organization (NGO) customers, as well as higher product sales. Other 2021 Assumptions. FOOTNOTES. (1) FOOTNOTES. (1)

Government

Government Vaccine Production Licensing

Amarin Reports Third Quarter 2020 Financial Results and Provides Business Update

The Pharma Data

NOVEMBER 4, 2020

As with much of the pharmaceutical industry, VASCEPA revenue and prescription growth have been adversely impacted by the COVID-19 pandemic. In addition, Amarin recognized licensing and royalty revenue of approximately $1.3 This compares with licensing and royalty revenue of $0.2 million and $8.9 million and $5.7 million and $1.1

Production

Production FDA Trials Licensing

Drug Discovery Digest

Emergent BioSolutions Announces 2021 Financial Guidance, Provides Preliminary 2020 Results

Amarin Reports Third Quarter 2020 Financial Results and Provides Business Update

Stay Connected